Amneal Pharmaceuticals, Inc. AMRX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s total liabilities & equity?
- Amneal Pharmaceuticals, Inc. (AMRX) reported total liabilities & equity of $3.54B in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s total liabilities & equity changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s total liabilities & equity increased by 5.2% year-over-year, from $3.37B to $3.54B.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s total liabilities & equity has grown at a -1.7% compound annual growth rate (CAGR), from $4.01B to $3.68B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.